Midwest Professional Planners, Ltd. Vertex Pharmaceuticals Inc Transaction History

Midwest Professional Planners, Ltd.

$324 Million
Q3 2024

A detailed history of Midwest Professional Planners, Ltd. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Midwest Professional Planners, Ltd. holds 3,590 shares of VRTX stock, worth $1.62 Million. This represents 0.51% of its overall portfolio holdings.

Number of Shares

3,590

Previous 3,271 9.75%

Holding current value

$1.62 Million

Previous $1.53 Million 8.87%

% of portfolio

0.51%

Previous 0.52%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$460.0 - $505.78 $146,740 - $161,343	319 Added 9.75%	3,590 $1.67 Million
Q2 2024 Aug 06, 2024	BUY	$392.81 - $485.53 $83,275 - $102,932	212 Added 6.93%	3,271 $1.53 Million
Q1 2024 May 09, 2024	BUY	$407.69 - $446.08 $145,545 - $159,250	357 Added 13.21%	3,059 $1.28 Million
Q4 2023 Feb 15, 2024	BUY	$343.0 - $410.68 $58,996 - $70,636	172 Added 6.8%	2,702 $1.1 Million
Q3 2023 Nov 13, 2023	BUY	$338.18 - $362.46 $144,064 - $154,407	426 Added 20.25%	2,530 $879,000
Q2 2023 Aug 07, 2023	BUY	$314.42 - $351.91 $140,231 - $156,951	446 Added 26.9%	2,104 $740,000
Q1 2023 May 15, 2023	BUY	$283.23 - $323.1 $54,380 - $62,035	192 Added 13.1%	1,658 $522,000
Q4 2022 Feb 10, 2023	BUY	$285.76 - $321.48 $75,440 - $84,870	264 Added 21.96%	1,466 $423,000
Q3 2022 Nov 10, 2022	BUY	$273.83 - $305.53 $28,478 - $31,775	104 Added 9.47%	1,202 $348,000
Q2 2022 Aug 09, 2022	BUY	$234.96 - $292.55 $34,304 - $42,712	146 Added 15.34%	1,098 $309,000
Q1 2022 May 11, 2022	BUY	$221.42 - $260.97 $210,791 - $248,443	952 New	952 $248,000

Others Institutions Holding VRTX

# of Institutions

1,721

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Midwest Professional Planners, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Midwest Professional Planners, Ltd. with notifications on news.

Account

Midwest Professional Planners, Ltd. Vertex Pharmaceuticals Inc Transaction History